Cargando…

A Novel Homodimer Peptide–Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy

Tumor-targeting peptide–drug conjugates (PDCs) have become a focus of research in recent years. However, due to the instability of peptides and their short in vivo effective half-life, they have limited clinical application. Herein, we propose a new DOX PDC based on a homodimer HER-2-targeting pepti...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shurong, Tian, Ye, Jiang, Sujun, Wang, Zihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003747/
https://www.ncbi.nlm.nih.gov/pubmed/36902021
http://dx.doi.org/10.3390/ijms24054590